Safety Study of Replagal® Therapy in Children With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 12, 2011

Primary Completion Date

April 17, 2013

Study Completion Date

April 17, 2013

Conditions
Fabry Disease
Interventions
BIOLOGICAL

Replagal (agalsidase alfa)

0.2 mg/kg administered over 40 minutes every other week (EOW)

Trial Locations (5)

22152

O & O Alpan LLC, Fairfax

27710

Duke University Medical Center, Durham

30033

Emory Division of Medical Genetics, Decatur

75246

Baylor University Medical Center, Dallas

84132

University of Utah Hospital, Salt Lake City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY